RXi Closes Acquisition of Apthera

RXi bought the firm for around $7.2 million in order to accelerate its move from a research-based company to a clinical-stage one.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.